LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT): Nasdaq/NYSE listing notice — Nasdaq Panel grants Lixte extension to July 3, 2025 for equity compliance

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lixte received extension from Nasdaq Hearings Panel after April 3 hearing on equity deficiency.
Must demonstrate minimum $2.5M stockholders' equity by July 3, 2025 to remain listed.
Common stock (LIXT) and warrants (LIXTW) continue trading on Nasdaq during extension.
Company pursuing measures but warns no assurance of regaining compliance; delisting risk persists.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 17, 2025, the Company received notice that the Nasdaq Hearings Panel (the “Panel”) had granted the Company an extension in which to regain compliance with all continued listing rules of the Nasdaq Capital Market. The Panel’s determination follows a hearing on April 3, 2025, at which the Panel considered the Company’s plan to regain compliance with the Equity Rule. As a result of the extension, the Panel granted the Company’s request for continued listing on the Nasdaq Capital Market, provided that the Company demonstrates compliance with the Equity Rule and all other continued listing re

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-005466

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.